FAQ: Teplizumab and Its Expanded FDA Indication

This FAQ was fact-checked by Jennifer Goldman, PharmD, CDCES, BC‑ADM, FCCP​​.​

In April 2026, the FDA approved an expanded indication for teplizumab-mzwv (Tzield; Sanofi) to include adults and children as young as 1 year with stage 2 type 1 diabetes (T1D). This supplemental biologic license application (sBLA) builds on the drug's original 2022 approval and marks a meaningful shift in how the pharmacy community must think about disease-modifying therapy in autoimmune T1D. For pharmacists, understanding the drug's mechanism, patient selection criteria, dosing, monitoring, and counseling requirements is essential as this therapy reaches an increasingly young population.

Q1: What is teplizumab, and what was it originally approved for?

Teplizumab is a humanized anti-CD3 monoclonal antibody first approved by the FDA in November 2022, making it the first disease-modifying therapy approved for autoimmune T1D in the US.

The original indication targeted adult and pediatric patients 8 years and older with stage 2 T1D, with the goal of delaying progression to stage 3 T1D. The pivotal phase 2 TN-10 clinical trial (NCT01030861) demonstrated that a single 14-day course of teplizumab delayed the median onset of stage 3 T1D by approximately 48 months compared with approximately 24 months in the placebo group—roughly a 2-year delay in clinical disease onset.

Q2: What is the new FDA-approved indication as of 2026?

On April 22, 2026, the FDA approved an sBLA for teplizumab, expanding its age indication from 8 years and older down to 1 year and older. Therapeutically, expanded indication is the same as the first: delay the onset of stage 3 T1D in patients diagnosed with stage 2 T1D. The approval was granted under priority review, reflecting the recognized unmet need for early immunomodulatory intervention in very young children who face unique risks from rapid disease progression and the challenges of managing insulin-dependent diabetes at a very small body size and with complete dependence on caregivers.

Q3: What is the difference between stage 2 and stage 3 type 1 diabetes?

Pharmacists counseling patients and families benefit from understanding the staging framework:

• Stage 1 T1D: The immune system has begun attacking beta cells; 2 or more islet autoantibodies are present, but blood glucose remains normal, and the patient is asymptomatic.
• Stage 2 T1D: Multiple islet autoantibodies are present, and dysglycemia (abnormal glucose tolerance) is now detectable on testing; however, the patient still has no clinical symptoms and has not yet lost enough beta-cell function to require insulin.
• Stage 3 T1D: Beta-cell destruction has progressed to the point where clinical symptoms appear (eg, polyuria, polydipsia, weight loss) and the patient requires insulin to manage their disease. This is the stage typically diagnosed in routine clinical care.

Teplizumab is indicated specifically during the stage 2 window—before the patient is symptomatic or insulin-dependent—with the goal of preserving remaining beta-cell function and buying time before stage 3 onset.

Q4: Why does the age expansion matter clinically?

Very young children with stage 2 T1D face a disproportionately high burden of disease. Research has shown that teplizumab is most effective when initiated before significant beta-cell loss, suggesting that earlier intervention in high-risk children is particularly valuable. The expansion to 1 year of age is significant for several reasons:

• Children under 8 years of age are at elevated risk of rapid progression from stage 2 to stage 3, often without warning signs recognizable to caregivers.
• Managing insulin-dependent diabetes in toddlers and young children is especially challenging due to small body size, variable eating patterns, inability to communicate symptoms, and complete reliance on adult caregivers for every aspect of diabetes management.
• Delaying insulin dependence by even 1 to 2 years during early childhood can have a meaningful impact on quality of life for the child and the family, reducing the burden of glucose monitoring, insulin administration, and hypoglycemia risk during developmentally critical years.

Q5: What clinical trial data support the expanded indication?

The expanded approval is supported by 1-year interim data from the PETITE-T1D clinical trial (NCT05757713), a single-arm, open-label, multicenter phase 4 trial evaluating the safety and pharmacokinetics of teplizumab in young children with stage 2 T1D. The study enrolled 23 patients with a mean age of approximately 4.8 years.

The data provided the FDA with evidence of acceptable safety and comparable pharmacokinetics in this younger age group, supporting the conclusion that the benefit-risk profile observed in older patients extends to children aged 1 year and above. The trial remains ongoing, and full study data are still maturing.

Q6: How is teplizumab administered, and what are the pharmacist's responsibilities around dispensing and preparation?

Teplizumab is administered once daily over 14 days. Key administration points for pharmacists to know:

• The drug is diluted in normal saline and infused daily for 14 days—typically in an outpatient infusion setting or specialty clinic.
• Dose is calculated using body surface area, which is particularly important in the newly approved pediatric population, where patients may weigh as little as 8 to 10 kg. Patients 8 years and older receive treatment over a 30-minute period, and those 1 year and younger than 8 years receive treatment over a 2-hour period.
• Pharmacists in health-system settings should confirm appropriate dose calculation per current prescribing information and flag any discrepancies, given the wide weight range now covered by the indication.
• The drug requires cold-chain storage and specialty pharmacy handling; it is not typically stocked in community pharmacy settings.
• Patients and caregivers should receive thorough counseling before the first infusion, including what to expect during the 14-day course and which adverse effects (AEs) to report.

Q7: What are the key safety considerations and monitoring parameters?

• AEs: The most common AEs are lymphopenia, vomiting, rash, leukopenia, diarrhea, and headache.
• Cytokine release syndrome (CRS): Although not common, this serious AE can occur within the first 5 days of infusion. Symptoms include fever, nausea, fatigue, headache, and chills. Pharmacists should ensure patients and caregivers can recognize AEs and know when to contact their care team. For CRS, they can premedicate and monitor for symptoms, and may temporarily pause dosing for 1 or 2 days before finishing the 14-day treatment period.
• Hypersensitivity reactions: Premedication with an antihistamine, antipyretic, or antiemetic is often employed prior to infusion; pharmacists should verify that appropriate premedications are prescribed.
• Infections: Transient immunosuppression increases infection risk; patients should be monitored and counseled to report signs of infection during and after treatment.
• Rash: A self-limited rash is commonly reported, usually appearing within the first week of treatment.
• Black Box Warning: The FDA label warns of serious, life-threatening cases of viral reactivation (eg, Epstein-Barr virus and cytomegalovirus). Patients who are already immunocompromised are at increased risk for infections.

In the pediatric population newly included under the expanded label, monitoring is especially critical given developmental considerations, limited ability to self-report symptoms, and the potentially higher vigilance required from caregivers.

Q8: How should pharmacists counsel families about what teplizumab is—and what it is not?

This is the most important counseling task. Families may come to the pharmacy with significant questions or misconceptions. Key messages include the following:

• Teplizumab does not cure T1D. It delays, not prevents, progression to stage 3. Parents, caregivers, and/or guardians should understand that it remains possible that stage 3 disease can eventually develop, but the window of insulin independence may be meaningfully extended.
• It is a 1-time 14-day course, not a chronic therapy. Repeat dosing protocols remain under investigation.
• Screening is required to identify stage 2 disease. Patients must have confirmed multiple islet autoantibodies and documented dysglycemia to be eligible. Families asking about testing should be referred to an endocrinologist experienced in T1D autoimmunity screening.
• The infusion schedule requires commitment. Fourteen consecutive daily infusions represent a significant logistical burden for families, particularly those with young children. Pharmacists can help families plan around this.
• Support resources exist. Organizations such as JDRF (now Breakthrough T1D) and TrialNet offer screening programs and can help connect at-risk families with appropriate monitoring.

Q9: Are there any drug interactions or contraindications to be aware of?

• Teplizumab is not recommended for patients with active serious or chronic infections. Patients should be monitored during and after treatment, and discontinue treatment if an infection develops.
• To avoid excess immunosuppression and infection risk, teplizumab is not recommended with other immunosuppressive agents.
• Administer live vaccines at least 8 weeks prior to treatment. Live vaccines are not recommended during treatment or up to 52 weeks after treatment. Inactivated/mRNA vaccine must be administered at least 2 weeks before treatment.
• During treatment, regularly monitor lymphocyte counts and monitor patients for signs and symptoms of viral reactivation during treatment and for at least 2 months following the last infusion. If viral reactivation is suspected, discontinue treatment and obtain viral load. If viral reactivation is confirmed, permanently discontinue teplizumab.
• As with all biologics, there is a theoretical risk of malignancy with long-term immune modulation, although this has not been a prominent finding in the clinical program to date.

Pharmacists should conduct a thorough medication review prior to the infusion course and communicate with the prescribing team about any concurrent immunomodulatory agents.

Summary for Clinical Practice

The recent FDA-approved expansion of teplizumab to children as young as 1 year of age represents a landmark moment in the pharmacotherapy of autoimmune T1D. For pharmacists, this means new responsibilities: recognizing eligible patients, counseling families on realistic expectations, ensuring appropriate weight-based dosing and cold-chain handling, and monitoring for AEs in a uniquely vulnerable pediatric population. As the only disease-modifying therapy available for T1D, teplizumab occupies a category of its own, and pharmacists remain essential partners in ensuring it is used safely and effectively.